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1. Introduction 
Myotonic dystrophies (DMs) are the most common adult neuromuscular diseases of genetic origin 
that involve multiple organs and tissues, especially the skeletal muscles [1]. The molecular causes 
are linked to the pathological expansion of repeated nucleotide sequences in specific genes: these 
mutant sequences are transcribed into expanded RNAs that sequester splicing factors, with 
consequent alterations in the RNA and protein metabolism. Currently, no therapy is available for 
DMs, and treatments are only aimed at managing symptoms. Some molecules (e.g., pentamidine or 
morpholino oligonucleotides) proved to be efficient in binding expanded RNA thus mitigating the 
pathological signs of DMs in experimental models. Actually, the therapeutic applications of these 
compounds is impaired by their low bioavailability or high systemic toxicity. Nanoparticles (NPs) 
could be an innovative solution to face these problems thanks to their ability to protect drugs from 
enzimatic degradation and to target specific cells or tissues. The aim of the present investigation 
was to assess the biocompatibility of novel hyaluronic acid (HA)-based NPs, and prove their ability 
of delivering pentamidine isothionate (PTM) to skeletal muscle cells in vitro.  
 
2. Materials and Methods 
HA-NPs and HA-NPs loaded with PTM (Loaded-NPs) were manufactured by ionic gelation 
technique (Carton et al., Submitted). Fluorescent HA-NPs (Fluo-NPs) were obtained by using HA 
labelled with fluorescein isothionate. The size and polydispersity index (PdI) were assessed by 
Dynamic Light Scattering. Murine C2C12 myoblasts were grown in Dulbecco’s modified Eagle 
medium at 37°C in a 5% CO2 humidified  atmosphere. For cytotoxicity assays, cells were seeded in 
96-multiwell plates while for fluorescence and transmission electron microscopy (TEM) they were 
planted onto glass coverslips in 24-multiwell plates. After 24h, cells were treated with the NPs. 
Untreated cells were used as absolute control. MTT viability assay was performed following the 
administration of blank HA-NPs, free PTM or Loaded-NPs at different concentrations for 2, 24 and 
48 h. For fluorescence microscopy, the cells were incubated with Fluo-NPs for 2 and 24 h, fixed 
with 4% paraformaldehyde, and stained with Phalloidin-Atto 594; nuclei were counterstained with 
Hoechst 33342. For TEM, cells were fixed with 2.5% glutaraldehyde/2% paraformaldehyde, post-
fixed with OsO4 and potassium ferrocyanide, dehydrated and embedded in Epon resin.  
 
3. Results and conclusions 
NPs ranged 250 to 300 nm in size, with PdI <0.1, and PTM encapsulation efficency of 80%. 
Viability assays showed that blank HA-NPs induce an increase of cell death only at the highest 
concentration tested for long incubation times (48 h), thus demonstrating their good 
biocompatibility; actually, no cytological alterations were ever observed at TEM following 
administration of blank HA-NPs.  As expected, free PMT induced concentration-dependent cell 
death; similar evidence was obtained after PMT administration via HA-NP, when cell mortality was 
sometimes even higher. Fluorescence microscopy (Figure 1) showed that Fluo-NPs are rapidly 
(<30min) and efficiently internalized by the cells in a time-dependent manner. TEM (Figure 2) 
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revealed that HA-NPs are internalized individually via endocytosis and localize throughout the 
cytoplasm, being never observed inside the cell nuclei. HA-NPs rapidly escape endosomes occuring 
free in the cytosol and, after 24 h, they may form large clusters (Figure 2b). 
 
 
 
Figure 1. Confocal fluorescence micrographs of C2C12 cells treated with Fluo-NPs (green) for 30 min (a) 
and 24 h (b). Actin cytoskeleton in red (Phalloidin-Atto 594), nucleus in blue (Hoechst 33342). Bars: 50 µm. 
 
 
 
  Figure 2. TEM micrographs of C2C12 cells treated with HA-NPs (arrow) for 2 h (a) and 24 h (b). Note the 
huge accumulation of NPs (asterisks) in the cytoplasm after 24 h. N: nucleus. Bars: 500 nm (a), 1 µm (b). 
 
We may conclude that, due to the good encapsulation efficiency and the excellent capability to enter 
and accumulate inside C2C12 cells, Loaded-NPs cause a rapid and massive intracellular release of 
PMT which can account for the high cell mortality observed. We may hypothesize that HA-NPs 
loaded with very low PMT concentrations would be able to induce therapeutic effects on DM 
muscle cells with reduced cytotoxicity. Studies are presently in progress to verify this hypothesis. 
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